title: [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
abstract: Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain. Re-188 is a generator-produced radionuclide emitting high energy beta and gamma rays and having a relative short physical half-life makes it of especially interesting for therapeutic purpose. Seven patients (pts) with multiple painful bone metastases were treated with Re-188 HEDP. Five pts with prostate cancer and 2 pts with breast cancer received a fixed activity of 3000 MBq of Re-188 HEDP intravenously in two steps. Complete blood counts were determined, blood chemistry examinations and urine-analysis were performed before and 1, 2, 3, 4, 6, 8, 12 weeks following the treatment. A visual analogue score, a verbal rating scale, the Spitzer index and the Karnofsky score were used to assess pain and performance status. Three hours after Re-188 HEDP administration at 1 m from the anterior mid-trunk of the pts gamma and at the patient body surface beta-radiation dose measurements were made, together with urine radioactivity measurements. Three pts become pain-free, 2 pts exhibited partial pain improvement and 1 patient gave no response to the Re-188 HEDP therapy. In 1 patient due to central nervous system metastasis the modification of the pain intensity could not be evaluated. Three pts displayed a flare reaction within 1 week after the treatment. Transient decreases in platelet and white blood cell counts were observed. There were no significant changes in the liver and renal functions. Radiation dose rate values of 6.3 +/- 1.0 microSv/h for gamma, and of 183 +/- 40 s-1 for beta-radiation were found. 25-32% of the administered dose was eliminated via the urinary tract in the first three hours. The preliminary data suggests that Re-188 HEDP is an effective radiopharmaceutical in treatment for metastatic bone pain. An administered activity of 3000 MBq can bring about a pain reduction without causing any clinically significant bone marrow toxicity.
authors.affiliation: Szegedi Tudományegyetem, Altalános Orvostudományi Kar, Szent-Györgyi Albert Orvos.
authors.forename: R
authors.initials: R
authors.lastname: Róka
authors.forename: T
authors.initials: T
authors.lastname: Séra
authors.forename: L
authors.initials: L
authors.lastname: Pajor
authors.forename: L
authors.initials: L
authors.lastname: Thurzó
authors.forename: J
authors.initials: J
authors.lastname: Láng
authors.forename: L
authors.initials: L
authors.lastname: Csernay
authors.forename: L
authors.initials: L
authors.lastname: Pávics
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications* / Q000201:enzymology / Q000556:secondary; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology*; D012968:Etidronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D010147:Pain Measurement; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D012211:Rhenium / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D011868:Radioisotopes; D012211:Rhenium; D000469:Alkaline Phosphatase; D012968:Etidronic Acid